Effect of Severe Renal Failure and Haemodialysis on the Pharmacokinetics of Levosimendan and Its Metabolites
- 1 January 2007
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 46 (3) , 235-246
- https://doi.org/10.2165/00003088-200746030-00004
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Population pharmacokinetics of levosimendan in patients with congestive heart failureBritish Journal of Clinical Pharmacology, 2003
- Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialThe Lancet, 2002
- Comparison of the Vasorelaxing Effect of Cromakalim and the New Inodilator, Levosimendan, in Human Isolated Portal VeinJournal of Pharmacy and Pharmacology, 2000
- Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysisBritish Journal of Clinical Pharmacology, 1998
- Principles of Drug Administration in Renal InsufficiencyClinical Pharmacokinetics, 1997
- Pharmacokinetics of Levosimendan in Healthy Volunteers and Patients with Congestive Heart FailureJournal of Cardiovascular Pharmacology, 1995
- Levosimendan (OR-1259), a Myofilament Calcium Sensitizer, Enhances Myocardial Contractility but Does Not Alter Isovolumic Relaxation in Conscious and Anesthetized DogsAnesthesiology, 1994
- Disease-Induced Variations in Plasma Protein LevelsClinical Pharmacokinetics, 1990
- Disease-Induced Variations in Plasma Protein LevelsClinical Pharmacokinetics, 1990
- Drug Kinetics and Artificial Kidneys1Clinical Pharmacokinetics, 1977